- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02221141
Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography
February 2, 2021 updated by: Laurence Gabriel
The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.
Actually the early diagnosis is important because a treatment exists that can prevent future complications.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
300
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laurence Gabriel
- Phone Number: 3623 +32 81 42 21 11
- Email: laurence.gabriel@uclouvain.be
Study Contact Backup
- Name: Karine Jourdan
- Phone Number: 3610 +32 81 42 21 11
- Email: karine.jourdan@uclouvain.be
Study Locations
-
-
-
Yvoir, Belgium, 5530
- Recruiting
- CHU Dinant-Godinne
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with left ventricular hypertrophy
Description
Inclusion Criteria:
- unexplained left ventricular hypertrophy
Exclusion Criteria:
- isolated septal hypertrophy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2013
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
December 1, 2022
Study Registration Dates
First Submitted
August 18, 2014
First Submitted That Met QC Criteria
August 19, 2014
First Posted (Estimate)
August 20, 2014
Study Record Updates
Last Update Posted (Actual)
February 3, 2021
Last Update Submitted That Met QC Criteria
February 2, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fabry Disease Cardioscreening
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Left Ventricular Hypertrophy
-
Nagoya UniversityUnknownHypertensive Left Ventricular HypertrophyJapan
-
University of LeipzigCompletedLeft Ventricular Hypertrophy | Left Ventricular Failure | Left Ventricular Non-compaction CardiomyopathyGermany
-
Tulane UniversityJohns Hopkins UniversityRecruitingEndothelial Dysfunction | Vascular Stiffness | Left Ventricular Dysfunction | Left Ventricular HypertrophyUnited States
-
Assistance Publique - Hôpitaux de ParisInstitute of Cardiometabolism and Nutrition, FranceNot yet recruitingLeft Ventricular HypertrophyFrance
-
Organon and CoCompletedHypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
-
Instituto de Urologia e NefrologiaUnknownLeft Ventricular HypertrophyBrazil
-
Yale UniversityRecruitingLeft Ventricular HypertrophyUnited States
-
Cardiovascular Academy Society, TurkeyCompletedLeft Ventricular HypertrophyTurkey
-
University of California, San FranciscoTerminatedLeft Ventricular HypertrophyUnited States
-
Ege UniversityFresenius Medical Care North AmericaCompletedLeft Ventricular HypertrophyTurkey